Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02851056 · ClinicalTrials.gov registry record · Early Phase 1
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT02851056: Completed Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT02851056 is a Early Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 14 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02851056, a Early Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to test what effects (good and bad) a new cancer vaccine will have on participants and their cancer, when administered before and after their autologous hematopoietic cell transplant (HCT). The name of the vaccine is called Dendritic Cell Survivin Vaccine (DC:AdmS). The vaccine is made using the participant's own blood cells. The vaccine will contain a virus called an adenovirus, similar the virus that causes the common cold. The virus has been changed so it cannot infect humans and cause infections. The vaccine will be prepared at Moffitt Cancer Center in the Cell Therapy Laboratory Facility.
Primary Outcome
Complete Response: A treatment outcome where there are ≤5% plasma cells in the bone marrow and no evidence of myeloma proteins in the serum or urine as measured by standard laboratory techniques.
Interventions
- BIOLOGICAL Prevnar 13
- BIOLOGICAL Survivin Vaccine
- PROCEDURE Autologous Hematopoietic Cell Transplantation
- DRUG Granulocyte-colony Stimulating Factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-09-27 |
| Est. Completion | 2018-08-09 |
| Phase | Early Phase 1 |
What the finished NCT02851056 record still lists
NCT02851056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 4 interventions - of which Prevnar 13 is the first listed.
NCT02851056 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02851056 about?
NCT02851056 is a clinical study titled "Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)". The purpose of this study is to test what effects (good and bad) a new cancer vaccine will have on participants and their cancer, when administered before and after their autologous hematopoietic cell transplant (HCT). The name of the vaccine is called Dendritic Cell Survivin Vaccine (DC:AdmS). The...
What is the current status of trial NCT02851056?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2016-09-27. Estimated completion is 2018-08-09.
What interventions are being tested in trial NCT02851056?
The interventions under investigation include: Prevnar 13 (BIOLOGICAL), Survivin Vaccine (BIOLOGICAL), Autologous Hematopoietic Cell Transplantation (PROCEDURE), Granulocyte-colony Stimulating Factor (DRUG).
Who is sponsoring clinical trial NCT02851056?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02851056's enrollment target sits among peer trials
14 1475th of 2000 higher than 498 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy